Wegovy Pill Just Changed: Why Lilly Stock Could Still Win
A new oral Wegovy launch is reshaping GLP-1 dynamics. Even with Novo Nordisk gaining ground, Eli Lilly stock could st...
Discover credit cards that provide cash rewards without annual fees. Make your spending count!
26,108 articlesA new oral Wegovy launch is reshaping GLP-1 dynamics. Even with Novo Nordisk gaining ground, Eli Lilly stock could st...
Set up your weekend with a curated mix of Friday reads for investors. This guide rounds up 10 must-check pieces that ...
BridgeBio's Q1 2026 earnings narrative is more than quarterly numbers—it's a roadmap for the year ahead. This guide e...
CoreWeave's backlog booming has caught the eye of investors eyeing AI infrastructure. This piece breaks down whether ...
Applied Materials reports a robust free cash flow figure for Q1 2026, but the stock fell as traders questioned how lo...
A Tony moment becomes a teachable moment for money and planning. This feature breaks down how Broadway earnings work,...
Investors are increasingly betting against Wall Street with inverse ETFs. This article explains how these funds work,...
Microsoft is doubling down on AI. This article lays out scenarios, risks, and concrete steps to understand where will...
As Bausch Health prepares its Q4 2025 results, investors want clarity on margins, debt, and the pipeline. This guide ...
In mid-2026, demand dynamics are reasserting themselves as the key driver behind housing trends. With supply still co...
SkyX’s Q1 2026 results hint at a company in transition: solid top-line momentum paired with ongoing investments. This...
A sharp pullback in the IGV ETF puts a spotlight on Oracle’s ability to generate free cash flow amid AI investments. ...